Georgia-based Danimer Scientific Joins White House-hosted Summit on Biotech and Biomanufacturing
Tuesday, September 20th, 2022
Danimer Scientific, Inc. chief executive officer Stephen Croskrey will be taking part in a high-level Summit on Biotechnology & Biomanufacturing for the American Bioeconomy, being hosted today by the White House Administration.
The summit, which will be livestreamed here, celebrates the vision, innovation and dedication across the United States to developing bio-based solutions to global challenges facing the country, and is being held in conjunction with President Biden’s Sept. 12, 2022, executive order launching a National Biotechnology and Biomanufacturing Initiative to ensure that products invented in the United States can be manufactured here as well. The president also recently signed the landmark CHIPS & Science Act, which makes historic investments to strengthen American manufacturing, research and development, science and technology.
At the summit, Croskrey will take part in a panel on biomanufacturing for the bioeconomy. The summit will also include a high-level roundtable with members of Congress, cabinet secretaries, and other industry and academic leaders, as well as a panel on biotechnology research and development to solve pressing challenges.
“I’m honored to be included in this summit on behalf of Danimer Scientific and the bioplastics industry,” Croskrey said. “Since our company’s founding in 2004, Danimer has been laser-focused on finding environmentally friendly, economically feasible solutions to the ever-growing plastic waste crisis. I look forward to working with the White House Administration to advance President Biden’s executive order and to continue developing and producing biodegradable products to reduce humans’ impact on our environment.”
Biotechnology utilizes microbes to make specialty chemicals and compounds in a process called biomanufacturing, which is increasingly being embraced as an alternative to petrochemical-based production to make plastics, fuels, materials and medicines. According to industry analysis, bioengineering could account for more than a third of global output of manufacturing industries before the end of the decade — almost $30 trillion in value.